臨床外科76巻2号

2021年02月発行

特集 外科医のための—悪性腫瘍補助療法のすべて 各論

結腸癌の術後補助化学療法：FOLFOXとCAPOX

著者： 中村真穂¹ 谷口浩也¹

所属機関： ¹国立がん研究センター東病院消化管内科

ページ範囲：P.169 - P.175

【ポイント】
◆補助化学療法は再発抑制と治癒率の向上が目的であり，適切な治療を安全に完遂することが重要である．
◆Stage Ⅲ結腸癌に対する術後補助化学療法は種々の臨床試験を経て有用性が確立され，FOLFOX療法およびCAPOX療法は，標準治療としてガイドラインにも記載されている．
◆Stage Ⅱ結腸癌のなかに再発高リスク群を設定し，期待される効果と想定される副作用を十分説明したうえで術後補助化学療法を行うことが推奨されている．
◆IDEA試験の結果を踏まえて，再発リスクに応じた治療期間の個別化が重要視されている．

参考文献

1）NIH consensus conference：Adjuvant therapy for patients with colon and rectal cancer. JAMA 264：1444-1450, 1990

2）André T, Boni C, Mounedji-Boudiaf L, et al：Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer（MOSAIC）Investigators：Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350：2343-2351, 2004

3）Haller DG, Tabernero J, Maroun J, et al：Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage Ⅲ colon cancer. J Clin Oncol 29：1465-1471, 2011

4）Kuebler JP, Wieand HS, O'Connell MJ, et al：Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage Ⅱ and Ⅲ colon cancer：results from NSABP C-07. J Clin Oncol 25：2198-2204, 2007

5）André T, Boni C, Navarro M, et al：Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage Ⅱ or Ⅲ colon cancer in the MOSAIC trial. J Clin Oncol 27：3109-3116, 2009

6）Yothers G, O'Connell MJ, Allegra CJ, et al：Oxaliplatin as adjuvant therapy for colon cancer：updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29：3768-3774, 2011

7）Yoshida M, Ishiguro M, Ikejiri K, et al：S-1 as adjuvant chemotherapy for stage Ⅲ colon cancer：a randomized phase Ⅲ study（ACTS-CC trial）. Ann Oncol 25：1743-1749, 2014

8）Yoshino T, Kotaka M, Shinozaki K et al：JOIN trial：treatment outcome and recovery status of peripheral sensory neuropathy during a 3-year follow-up in patients receiving modified FOLFOX6 as adjuvant treatment for stage Ⅱ/Ⅲcolon cancer. Cancer Chemother Pharmacol 84：1269-1277, 2019

9）Kotaka M, Yoshino T, Oba K, et al：Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage Ⅱ or Ⅲ colon cancer（JFMC41-1001-C2：JOIN trial）. Cancer Chemother Pharmacol 76：75-84, 2015

10）Shi Q, Sobrero AF, Shields AF, et al：Prospective pooled analysis of six phase Ⅲ trials investigating duration of adjuvant（adjuv）oxaliplatin-based therapy（3 vs 6 months）for patients（pts）with stage Ⅲ colon cancer（CC）：The IDEA（International Duration Evaluation of Adjuvant chemotherapy）collaboration. J Clin Oncol 35（suppl）：Abstr LBA1, 2017

11）Grothey A, Sobrero AF, Shields AF, et al：Duration of adjuvant chemotherapy for stage Ⅲ colon cancer. N Engl J Med 378：1177-1188, 2018

12）Sobrero AF, Andre T, Meyerhardtet JA, et al：Overall survival（OS）and long-term disease-free survival（DFS）of three versus six months of adjuvant（adj）oxaliplatin and fluoropyrimidine-based therapy for patients（pts）with stage Ⅲ colon cancer（CC）：Final results from the IDEA（International Duration Evaluation of Adj chemotherapy）collaboration. J Clin Oncol 38（Suppl）：#4004, 2020

13）Yoshino T, Yamanaka T, Kotaka D, et al：Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage Ⅲ colon cancer（CC）：Results from phase Ⅲ ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy（IDEA）Collaboration. Ann Oncol 28（Supple 5），2017 DOI：https://doi.org/10.1093/annonc/mdx440.017

14）Yoshino T, Kotaka M, Manaka D, et al：OS and long-term DFS with 3- vs. 6-month adjuvant oxaliplatin and fluoropyrimidine-based therapy for stage Ⅲ colon cancer patients：A randomized phase 3 ACHIEVE trial. Ann Oncol 31（Supple 4）：S411-S412, 2020 DOI：https://doi.org/10.1016/j.annonc.2020.08.512

15）Benson AB 3rd, Schrag D, Somerfield MR, et al：American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage Ⅱ colon cancer. J Clin Oncol 22：3408-3419, 2004 doi：10.1200/JCO.2004.05.063.

16）Schmoll HJ, Van Cutsem E, Stein A, et al：ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23：2479-2516, 2012

17）Iveson T, Sobrero AF, Yoshino T, et al：Prospective pooled analysis of four randomized trials investigating duration of adjuvant（adj）oxaliplatin-based therapy（3 vs 6 months｛m｝）for patients（pts）with high-risk stage Ⅱ colorectal cancer（CC）. J Clin Oncol 37（Supple）：#3501, 2019

18）Yoshino T, Yamanaka T, Shiozawa M, et al：ACHIEVE-2 trial：a randomized phase Ⅲ trial investigating duration of adjuvant（adj）oxaliplatin-based therapy（3 vs 6 months）for patients（pts）with high-risk stage Ⅱ colon cancer（CC）. Ann Oncol 30（suppl 5）：Abstr 5250, 2019

19）エルプラット インタビューフォーム2020年6月改訂（第15版）

20）Takimoto CH, Graham MA, Lockwood G, et al：Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res 13：4832-4839, 2007 doi：10.1158/1078-0432.CCR-07-0475.

21）Hershman DL, Lacchetti C, Dwokin RH, et al：Prevention and Management of Chemotherapy-InducedPeripheral Neuropathy in Survivors of Adult Cancers：American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 32：1941-1967, 2014

22）Lavoie Smith EM, Pang H, Cirrincione C, et al：Effect pf duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy. JAMA 309：1359-1367, 2013

23）NCCN Guidelines Version 4.2020 Colon Cancer〔https://www.nccn.org/professionals/physician_gls/default.aspx〕

24）Hata T, Honda M, Kobayashi M, et al：Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein：a multicenter randomized phase Ⅱ study（APOLLO）. Cancer Chemother Pharmacol 76：1209-1215, 2015